Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCCP on tooth whitener studies

This article was originally published in The Tan Sheet

Executive Summary

Guidance on product application, end points, size and definition of study populations, including subgroup, and study duration is included in the European Commission's Scientific Committee on Consumer Products' recently published "Guidance Document on Epidemiological and Clinical Studies on Tooth Whitening Products." The 1guidance responds to a March 2005 SCCP meeting in which the committee observed that there is an "absence of good data and long-term epidemiology studies that assess the possible adverse effects [of tooth whiteners] within the oral cavity" (2"The Tan Sheet" April 4, 2005, p. 16). Parameters such as the separate evaluation of hard and soft tissue effects and the evaluation of age groups since "differences in the degrees of mineralization of dental hard tissue may affect the treatment outcome," are also addressed...

You may also be interested in...



SCCP Upholds Opinion On Tooth Whiteners With Hydrogen Peroxide

Adequate data do not exist to support the safety of tooth-whitening products containing up to 6% hydrogen peroxide for over-the-counter use, the European Commission Scientific Committee on Consumer Products concludes in a recent opinion

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

Topics

UsernamePublicRestriction

Register

PS099459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel